Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:25 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
NCT00750698 · Syndax Pharmaceuticals · PHASE2 · terminated · last registry update 2023-07-06 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to business reasons, enrollment on the study was halted and the study terminated. The decision to close enrollment was not due to any safety concern.” | Open Targets' class: business administrative | Registry record, Syndax Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HDAC1 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-05-03Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Azacitidine + Entinostat (NCT01928576)
- 2024-04-22Results posted on the registry: Mirati Therapeutics Inc., Glesatinib + Sitravatinib (NCT02954991)
- 2024-04-22Also stopped (terminated): Mirati Therapeutics Inc., Glesatinib + Sitravatinib (NCT02954991)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision